Breaking News, Collaborations & Alliances

Dendreon and Shoreline Enter CMC Agreement

Marks Dendreon’s first manufacturing partnership since launch of new CMO division.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer, have formed an alliance to advance the future of iPSC-derived cellular therapies.   The alliance leverages Dendreon’s extensive man...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters